Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin

Doxorubicin is the most frequently used chemotherapeutic agent for the treatment of hepatocellular carcinoma. However, one major obstacle to the effective management of liver cancer is the drug resistance derived from the cancer stem cells. Herein, we employed a CD133 aptamer for targeted delivery of doxorubicin into liver cancer stem cells to overcome chemoresistance. Furthermore, we explored the efficacy of autophagy inhibition to sensitize liver cancer stem cells to the treatment of CD133 aptamer-doxorubicin conjugates based on the previous observation that doxorubicin contributes to the survival of liver cancer stem cells by activating autophagy. The kinetics and thermodynamics of aptamer-doxorubicin binding, autophagy induction, cell apoptosis, and self-renewal of liver cancer stem cells were studied using isothermal titration calorimetry, Western blot analysis, annexin V assay, and tumorsphere formation assay. The aptamer-cell binding andintracellular accumulation of doxorubicin were quantified via flow cytometry. CD133 aptamer-guided delivery of doxorubicin resulted in a higher doxorubicin concentration in the liver cancer stem cells. The combinatorial treatment strategy of CD133 aptamer-doxorubicin conjugates and an autophagy inhibitor led to an over 10-fold higher elimination of liver cancer stem cells than that of free doxorubicin in vitro. Future exploration of cancer stem cell-targeted delivery of doxorubicin in conjunction with autophagy inhibition in vivo may well lead to improved outcomes in the treatment of hepatocellular carcinoma.

[1]  H. Karimi-Sari,et al.  Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg) , 2022, Journal of clinical medicine.

[2]  W. Duan,et al.  The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells , 2021, Scientific Reports.

[3]  P. Zhao,et al.  Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma , 2021, Theranostics.

[4]  Jian-hui Jiang,et al.  Nucleic Acid Aptamers for Molecular Diagnostics and Therapeutics: Advances and Perspectives. , 2020, Angewandte Chemie.

[5]  David R. Bell,et al.  In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers , 2020, Proceedings of the National Academy of Sciences.

[6]  W. Liao,et al.  Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma , 2020, Infectious Agents and Cancer.

[7]  Miguel Costas,et al.  AFFINImeter: A software to analyze molecular recognition processes from experimental data. , 2019, Analytical biochemistry.

[8]  B. Guo,et al.  Exosomes derived from HBV-associated liver cancer promote chemoresistance by upregulating chaperone-mediated autophagy , 2018, Oncology letters.

[9]  A. LeBeau,et al.  The role of CD133 in cancer: a concise review , 2018, Clinical and Translational Medicine.

[10]  Jianmin Yang,et al.  HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma , 2018, Cell Death & Disease.

[11]  W. Duan,et al.  Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery , 2017, Theranostics.

[12]  Wei-Chieh Huang,et al.  The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients , 2017, BMC Cancer.

[13]  S. Kaneko,et al.  The evolving concept of liver cancer stem cells , 2017, Molecular Cancer.

[14]  Wei-Wei Zhang,et al.  Hepatitis B virus X protein promotes the stem-like properties of OV6+ cancer cells in hepatocellular carcinoma , 2017, Cell Death & Disease.

[15]  F. Xue,et al.  Autophagy-deficiency in hepatic progenitor cells leads to the defects of stemness and enhances susceptibility to neoplastic transformation. , 2016, Cancer letters.

[16]  A. Kouzani,et al.  Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors , 2015, Theranostics.

[17]  Julia M. Shifman,et al.  How Structure Defines Affinity in Protein-Protein Interactions , 2014, PloS one.

[18]  Dong-hao Wu,et al.  Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma , 2014, Tumor Biology.

[19]  F. Sinicrope,et al.  Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage and Maintain Centrosome Stability in Colorectal Cancer Cells , 2014, PloS one.

[20]  D. Schneider,et al.  Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor , 2014, The Journal of Biological Chemistry.

[21]  F. Locatelli,et al.  Multidrug Resistance and Cancer Stem Cells in Neuroblastoma and Hepatoblastoma , 2013, International journal of molecular sciences.

[22]  Rong Li,et al.  Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. , 2013, Cancer letters.

[23]  Tao Wang,et al.  RNA aptamers targeting cancer stem cell marker CD133. , 2013, Cancer letters.

[24]  R. Shao,et al.  CD133+EpCAM+ Phenotype Possesses More Characteristics of Tumor Initiating Cells in Hepatocellular Carcinoma Huh7 Cells , 2012, International journal of biological sciences.

[25]  D. Hwang,et al.  CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. , 2012, Cancer letters.

[26]  Meng-chao Wu,et al.  Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines , 2011, BMC gastroenterology.

[27]  Wei Chen,et al.  Anti-human CD133 monoclonal antibody that could inhibit the proliferation of colorectal cancer cells. , 2010, Hybridoma.

[28]  W. Wätjen,et al.  Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. , 2010, Toxicology.

[29]  Markus R. Wenk,et al.  Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-Kinase* , 2010, The Journal of Biological Chemistry.

[30]  G. Stassi,et al.  The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. , 2010, Cancer research.

[31]  M. Wicha,et al.  Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin Signaling , 2009, PLoS biology.

[32]  M. Stone,et al.  In silico selection of RNA aptamers , 2009, Nucleic acids research.

[33]  Gwendolyn M. Stovall,et al.  Technical and biological issues relevant to cell typing with aptamers. , 2009, Journal of proteome research.

[34]  Sangdun Choi,et al.  Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy , 2005, Nature Biotechnology.

[35]  W Bruce Turnbull,et al.  On the value of c: can low affinity systems be studied by isothermal titration calorimetry? , 2003, Journal of the American Chemical Society.

[36]  H. Kozłowski,et al.  New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. , 2003, Chemico-biological interactions.

[37]  J. Dufour,et al.  Cell lines , 2012, Spermatogenesis.

[38]  C. Cullinane,et al.  DNA sequence‐specific adducts of adriamycin and mitomycin C , 1989, FEBS letters.

[39]  T. Yamane,et al.  Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. , 1984, Gan.

[40]  J. Urbanowicz,et al.  Hepatitis B surface antigen produced by a human hepatoma cell line , 1976, British Journal of Cancer.

[41]  V. M. Heatwole.  TUNEL assay for apoptotic cells. , 1999, Methods in molecular biology.